CA
CAMP.US CAMP4 THERAPEUTICS CORPORATION
- Market cap
- USD 238M
- P/E
- -
- P/B
- 2.40x
- ROE
- -100.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CAMP.US undervalued?
Graham numberThe Graham number of CAMP4 THERAPEUTICS CORPORATION cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CAMP4 THERAPEUTICS CORPORATION fundamental analysis
No fundamental analysis for CAMP4 THERAPEUTICS CORPORATION yet.
CAMP4 THERAPEUTICS CORPORATION stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Thera…
Full company profileCAMP4 THERAPEUTICS CORPORATION financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CAMP4 THERAPEUTICS CORPORATION annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 351M | 366M | 364M | 366M | 309M | 296M | 295M | 350K | 652K | 3.50M | 6.63M |
| Gross Profit | 143M | 151M | 148M | 143M | 122M | 122M | 109M | 350K | 652K | 1.86M | 5.24M |
| Operating Income | 1.34M | 7.96M | 19.7M | -16.8M | -6.83M | -13.5M | -24.7M | -51.9M | -53.1M | -52.1M | -54.0M |
| EBITDA | 24.7M | 31.4M | 47.1M | 15.2M | 8.47M | -2.64M | -24.2M | -50.2M | -51.4M | -50.4M | -98.7M |
| Net Income | -7.15M | 16.6M | 18.4M | -78.8M | -56.3M | -28.0M | -32.5M | -49.3M | -51.8M | -80.4M | -108M |
| EPS | -0.20 | 0.46 | 0.52 | -2.34 | -38 | -18 | -0.90 | -4.07 | -2.66 | -2.65 | -1.36 |
| Balance Sheet | |||||||||||
| Total Assets | 408M | 473M | 604M | 496M | 442M | 402M | 103M | 54.9M | 78.3M | 118M | 134M |
| Total Liabilities | 244M | 274M | 398M | 358M | 343M | 322M | 180M | 179M | 15.2M | 70.1M | 26.9M |
| Shareholders' Equity | 164M | 199M | 206M | 138M | 99.3M | 80.2M | -77.5M | -124M | 63.1M | 47.7M | 107M |
| Cash & Short-term Investments | 100M | 156M | 274M | 107M | 91.7M | 91.1M | 83.2M | 38.4M | 64.0M | 110M | 125M |
| Total Debt | 147M | 154M | 276M | 234M | 211M | 209M | 12.4M | 11.7M | 8.65M | 1.97M | 6.45M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 25.8M | 66.9M | 47.7M | 11.5M | 28.6M | -4.22M | -38.5M | -44.2M | -45.6M | -29.6M | -42.4M |
| Capital Expenditure | 7.96M | 8.34M | 10.4M | 21.3M | 11.4M | 13.3M | 4.03M | 678K | 441K | 279K | 1.16M |
| Free Cash Flow | 17.8M | 58.6M | 37.3M | -9.76M | 17.2M | -17.5M | -42.6M | -44.8M | -46.0M | -29.8M | -43.6M |
| Ratios | |||||||||||
| ROE | -4.4% | 8.4% | 8.9% | -57.1% | -56.7% | -34.9% | - | - | -82.0% | -168.5% | -100.6% |
| ROA | -1.8% | 3.5% | 3.0% | -15.9% | -12.7% | -7.0% | -31.7% | -89.7% | -66.1% | -68.2% | -80.4% |
| Net Profit Margin | -2.0% | 4.5% | 5.1% | -21.5% | -18.2% | -9.5% | -11.0% | -14,083.1% | -7,943.4% | -2,298.5% | -1,625.4% |
| Debt to Equity | 0.90x | 0.78x | 1.34x | 1.70x | 2.12x | 2.61x | - | - | 0.14x | 0.04x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CAMP4 THERAPEUTICS CORPORATION dividends
CAMP4 THERAPEUTICS CORPORATION has not paid dividends in the last 9 fiscal years.
Last stock split: 2:1 on Mar 25, 1996.
Who owns CAMP4 THERAPEUTICS CORPORATION
- Insiders 9.65%
- Institutions 80.07%
- Public & others 10.28%
- Shares outstanding 62.8M
- Free float 43.3M
Top funds holding CAMP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Select Biotechnology | 2.55M | 4.07% | +92.49% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.59M | 2.54% | +28.85% | Sep 2026 |
| Fidelity Growth Company Fund | 822K | 1.31% | +105.66% | Aug 2026 |
| iShares Russell 2000 ETF | 699K | 1.11% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 346K | 0.55% | +1.16% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 301K | 0.48% | -0.38% | Oct 2026 |
| Fidelity Growth Company K6 | 235K | 0.37% | +113.77% | Aug 2026 |
| Victory Science & Technology | 227K | 0.36% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 214K | 0.34% | +38.14% | Sep 2026 |
| Vanguard Russell 2000 ETF | 183K | 0.29% | +1.30% | Sep 2026 |
| Fidelity Series Growth Company | 166K | 0.26% | +175.87% | Aug 2026 |
| iShares Micro-Cap ETF | 94.9K | 0.15% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 76.7K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 75.8K | 0.12% | +24.31% | Sep 2026 |
| Fidelity Series Total Market Index | 63.4K | 0.10% | +31.37% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 59.1K | 0.09% | 0.00% | Sep 2026 |
| Victory RS Science and Technology A | 58.9K | 0.09% | 0.00% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 53.8K | 0.09% | 0.00% | Oct 2026 |
| Goldman Sachs ActiveBeta® US SmCp Eq ETF | 52.6K | 0.08% | 0.00% | Oct 2026 |
Top institutions holding CAMP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jupiter Topco LLC | 6.31M | 10.05% | 0.00% | Jun 2026 |
| 5AM Venture Management, LLC | 5.87M | 9.35% | 0.00% | Jun 2026 |
| FMR Inc | 4.90M | 7.82% | -0.59% | Jun 2026 |
| Vivo Capital, LLC | 4.25M | 6.77% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 2.58M | 4.10% | -2.15% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.96M | 3.12% | 0.00% | Jun 2026 |
| Trails Edge Capital Partners, LP | 1.93M | 3.08% | -0.34% | Jun 2026 |
| BlackRock Inc | 1.64M | 2.62% | +260.26% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.53M | 2.44% | -0.08% | Jun 2026 |
| Enavate Sciences GP, LLC | 1.43M | 2.27% | -34.93% | Jun 2026 |
| Stonepine Capital Management Llc | 1.39M | 2.21% | 0.00% | Jun 2026 |
| Harbourvest Partners, LLC | 1.27M | 2.03% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 796K | 1.27% | +107.84% | Jun 2026 |
| SummitTX Capital, L.P | 725K | 1.16% | +113.58% | Jun 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 654K | 1.04% | 0.00% | Jun 2026 |
| State Street Corp | 362K | 0.58% | +146.63% | Jun 2026 |
| Northern Trust Corp | 249K | 0.40% | +251.90% | Jun 2026 |
| The Goldman Sachs Group Inc | 241K | 0.38% | +208.12% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 226K | 0.36% | +15.93% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 221K | 0.35% | 0.00% | Jun 2026 |
CAMP4 THERAPEUTICS CORPORATION company profile
- Company name
- CAMP4 THERAPEUTICS CORPORATION
- Ticker
- CAMP.US
- Exchange
- USA Stocks
- Listed since
- Oct 11, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 48
- Fiscal year end
- December
- Address
- 100 Talcott Avenue, Watertown, MA, United States, 02472
- Phone
- 617 651 8867
- Website
- camp4tx.com
About CAMP4 THERAPEUTICS CORPORATION
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
CAMP4 THERAPEUTICS CORPORATION management
10- Mr. Joshua Mandel-BrehmCEO, President & Director · born 1983
- Dr. Richard A. Young Ph.D.Founder & Independent Director · born 1954
- Ms. Kelly GoldChief Financial Officer · born 1977
- Dr. Yuri Maricich M.B.A., M.D.Chief Medical Officer · born 1981
- Dr. Leonard I. Zon M.D.Founder & Chairman of Scientific Advisory Board
- Mr. Caleb MooreChief Business Operations Officer
- Dr. Daniel Tardiff Ph.D.Chief Scientific Officer · born 1980
- Ms. Michelle GatesSenior VP & Chief People Officer
- Ms. Alla Sigova Ph.D.Senior Vice President of Platform
- Dr. Satya Kuchimanchi Ph.D.Senior Vice President of Technical Operations